小儿中重度斑块型银屑病的治疗策略:聚焦生物制剂

IF 1.7 Q2 PEDIATRICS
Angelo Ruggiero, Antonio Portarapillo, Matteo Megna, Cataldo Patruno, Maddalena Napolitano
{"title":"小儿中重度斑块型银屑病的治疗策略:聚焦生物制剂","authors":"Angelo Ruggiero, Antonio Portarapillo, Matteo Megna, Cataldo Patruno, Maddalena Napolitano","doi":"10.2147/phmt.s389108","DOIUrl":null,"url":null,"abstract":"Abstract: Although psoriasis onset has been reported at any ages, in up to one-third of cases, it begins during childhood, with an estimated prevalence of about 2% in pediatric population. The management of moderate-to-severe forms of childhood psoriasis may represent a challenge for dermatologists, especially for parents’ concerns about the need of systemic treatments. However, a prompt safe and effective treatment is mandatory in these patients, due to the significative impact that psoriasis may have on their quality of life, with well-known consequences on psychological health of both patients and caregivers. Due to the relatively frequent parents’ refusal of systemic treatments, probably due to the fear of eventual adverse events, difficulties of oral or injective route, the management of moderate-to-severe forms still represents a challenge. Herein, we report a narrative review, aiming to resume the systemic treatments for pediatric psoriasis, focusing on the use of biologics and small molecules in the pediatric ages. The most widely used therapeutic strategies today for the pediatric population with moderate-severe psoriasis are traditional systemic therapies, while more innovative drugs such as biologics and small molecules now represent a somewhat unexplored but certainly promising field for unresponsive patients. Keywords: psoriasis, biologics, childhood, pediatric, small molecules, treatment","PeriodicalId":74410,"journal":{"name":"Pediatric health, medicine and therapeutics","volume":"15 3","pages":"0"},"PeriodicalIF":1.7000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics\",\"authors\":\"Angelo Ruggiero, Antonio Portarapillo, Matteo Megna, Cataldo Patruno, Maddalena Napolitano\",\"doi\":\"10.2147/phmt.s389108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Although psoriasis onset has been reported at any ages, in up to one-third of cases, it begins during childhood, with an estimated prevalence of about 2% in pediatric population. The management of moderate-to-severe forms of childhood psoriasis may represent a challenge for dermatologists, especially for parents’ concerns about the need of systemic treatments. However, a prompt safe and effective treatment is mandatory in these patients, due to the significative impact that psoriasis may have on their quality of life, with well-known consequences on psychological health of both patients and caregivers. Due to the relatively frequent parents’ refusal of systemic treatments, probably due to the fear of eventual adverse events, difficulties of oral or injective route, the management of moderate-to-severe forms still represents a challenge. Herein, we report a narrative review, aiming to resume the systemic treatments for pediatric psoriasis, focusing on the use of biologics and small molecules in the pediatric ages. The most widely used therapeutic strategies today for the pediatric population with moderate-severe psoriasis are traditional systemic therapies, while more innovative drugs such as biologics and small molecules now represent a somewhat unexplored but certainly promising field for unresponsive patients. Keywords: psoriasis, biologics, childhood, pediatric, small molecules, treatment\",\"PeriodicalId\":74410,\"journal\":{\"name\":\"Pediatric health, medicine and therapeutics\",\"volume\":\"15 3\",\"pages\":\"0\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric health, medicine and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/phmt.s389108\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric health, medicine and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/phmt.s389108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

摘要

摘要:尽管牛皮癣在任何年龄都有发病的报道,但在多达三分之一的病例中,牛皮癣始于儿童时期,估计在儿科人群中的患病率约为2%。中度至重度儿童牛皮癣的治疗对皮肤科医生来说可能是一个挑战,特别是对于父母担心需要全身治疗的问题。然而,由于牛皮癣可能对患者的生活质量产生重大影响,并对患者和护理人员的心理健康产生众所周知的后果,因此对这些患者进行及时安全和有效的治疗是必须的。由于相对频繁的家长拒绝系统治疗,可能是由于担心最终的不良事件,口服或注射途径的困难,中度至重度形式的管理仍然是一个挑战。在此,我们报道一篇叙述性的综述,旨在恢复小儿银屑病的全身治疗,重点是生物制剂和小分子在儿科时代的应用。目前,对于患有中重度牛皮癣的儿童人群,最广泛使用的治疗策略是传统的全身治疗,而更多的创新药物,如生物制剂和小分子药物,现在代表了一个尚未开发但肯定有前景的领域,用于无反应患者。关键词:银屑病,生物制剂,儿童,儿科,小分子,治疗
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
Abstract: Although psoriasis onset has been reported at any ages, in up to one-third of cases, it begins during childhood, with an estimated prevalence of about 2% in pediatric population. The management of moderate-to-severe forms of childhood psoriasis may represent a challenge for dermatologists, especially for parents’ concerns about the need of systemic treatments. However, a prompt safe and effective treatment is mandatory in these patients, due to the significative impact that psoriasis may have on their quality of life, with well-known consequences on psychological health of both patients and caregivers. Due to the relatively frequent parents’ refusal of systemic treatments, probably due to the fear of eventual adverse events, difficulties of oral or injective route, the management of moderate-to-severe forms still represents a challenge. Herein, we report a narrative review, aiming to resume the systemic treatments for pediatric psoriasis, focusing on the use of biologics and small molecules in the pediatric ages. The most widely used therapeutic strategies today for the pediatric population with moderate-severe psoriasis are traditional systemic therapies, while more innovative drugs such as biologics and small molecules now represent a somewhat unexplored but certainly promising field for unresponsive patients. Keywords: psoriasis, biologics, childhood, pediatric, small molecules, treatment
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信